Get your full text copy in PDF

Appropriate Sample Size for Standardization Parameters Estimation Reduces Misdiagnoses of Molecular-Based Risk Predictors in Breast Cancer

Aldana González-Montoro, Laura Prato, Federico Casares, Mónica Balzarini, Elmer Fernandez

Med Sci Tech 2017; 58:111-118

DOI: 10.12659/MST.905935

BACKGROUND: Accurate risk/outcome prediction, in which molecular signatures (MS) are playing an increasingly important role, is crucial for personalized therapy. Patients require an accurate diagnosis and an appropriate therapy assignment as soon as they arrive at the clinic. However, most MS require gene-based standardization through parameters estimated from an available population sample. Thus, the estimation of gene standardization parameters (SP) turns out to be crucial to avoid misdiagnoses. Although dependency on SP has been recognized, the effect of different sample sizes on estimation of and impact on therapy management has not been reported. Because this is key for clinical application, in the present study we evaluated the impact of SP on outcome prediction error due to sample size. For this, 2 well-known breast cancer (BC) subtype/risk predictors were used on real data under different recruitment scenarios.
MATERIAL AND METHODS: The PAM50 and Gene70 MS were fed with standardized gene expression profiles using SP estimated from different sample sizes to predict BC intrinsic subtypes and progression, respectively. Error sensitivity analysis was based on estimation of outcome prediction error rates against those obtained using SP estimated with all the patients in the cohort (our criterion standard). Seven BC cohorts including TCGA data (2014 subjects in total) were used.
RESULTS: We found that BC outcome prediction is very sensitive to the sample size used to estimate the MS standardization parameters. More than 20% of predicted classes can change when using small sample sizes to compute SP, and more than 20% of subjects can have their predicted outcome changed.
CONCLUSIONS: Patients might receive inappropriate therapy if the SP are not carefully dealt with. A pilot study to provide SP that yield a stable prediction is necessary. A method to evaluate the sufficiency of the size of the available sample for parameter estimation is proposed to guide prior pilot study development.

Keywords: Decision Support Techniques, Early Detection of Cancer

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

I agree